Xeltis announces completion of enrolment in EU Pivotal Trial for aXess and prepares for market approval ...Middle East

News by : (PR Newswire) -

- Enrolment completed - 120 patients with end-stage renal disease in 22 centers in Europe - Primary endpoint readouts anticipated in Q2 2025, first market approval expected in 2026 - Capability to obtain market approval is further strengthened with the appointment of Rob Eyers as Chief...

Read More Details
Finally We wish PressBee provided you with enough information of ( Xeltis announces completion of enrolment in EU Pivotal Trial for aXess and prepares for market approval )

Also on site :

Most Viewed News
جديد الاخبار